OnKure Therapeutics (NASDAQ:OKUR – Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.
Profitability
This table compares OnKure Therapeutics and Nautilus Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OnKure Therapeutics | N/A | -74.86% | -67.92% |
| Nautilus Biotechnology | N/A | -33.35% | -28.41% |
Analyst Ratings
This is a summary of recent recommendations and price targets for OnKure Therapeutics and Nautilus Biotechnology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OnKure Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
| Nautilus Biotechnology | 1 | 0 | 0 | 0 | 1.00 |
Insider and Institutional Ownership
91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 2.3% of OnKure Therapeutics shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares OnKure Therapeutics and Nautilus Biotechnology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OnKure Therapeutics | N/A | N/A | -$52.67 million | ($4.79) | -0.64 |
| Nautilus Biotechnology | N/A | N/A | -$70.78 million | ($0.50) | -4.54 |
Nautilus Biotechnology is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
OnKure Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.
Summary
OnKure Therapeutics beats Nautilus Biotechnology on 6 of the 11 factors compared between the two stocks.
About OnKure Therapeutics
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
